Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Protein Therapies
Sloning BioTechnology GmbH Raised EUR 4.7m in a First Closing of a Series E Equity Financing Round
November 22nd, 2007
Sloning BioTechnology GmbH, Puchheim (Munich), a Synthetic Biology company and the technology leader in Gene Synthesis announces the first closing of a series E financing round. LBBW Venture Capital GmbH, Stuttgart joined existing investors HBM BioVentures, Zurich, KfW Bankengruppe and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG, Jena who also participated in this series E financing round. The proceeds of this first closing with EUR 4.7m will be used to finance the internationalization of its Slonomics(TM) gene synthesis business and the further expansion of the unique gene mutant library product family: Slonomax(TM) - the intelligent library. Dr. Heinz...
Source: Genetics & Environmental Business Week (2007-11-22)
|
